Glenmark gets US FDA nod to expand RYALTRIS use in kids aged 6-12

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.0%Reaction day

₹2242.20

prior close

₹2245.80

announcement price

After-mkt

timing

Nifty Midcap 150market+0.4%-0.4% vs market

Pharmaceuticals peers, median of 165sector+0.1%-0.1% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.7

15m

-0.7

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.0+0.4-0.4+0.1-0.1

Next day

-1.6-0.7-0.9-1.5-0.1

-1.8-1.6-0.1-2.1+0.4

-1.8-1.7-0.1-2.3+0.5

-1.9-0.7-1.3-1.5-0.4

-2.7-0.7-2.0-2.2-0.4

-1.6-0.2-1.3-2.6+1.0

15d

+1.8+1.6+0.2+0.1+1.7

+3.4+1.4+2.0-0.7+4.1

+9.6-1.2+10.8+0.9+8.7

-2.1-8.2+6.0-6.0+3.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Glenmark's RYALTRIS nasal spray, already approved for adults and kids 12 and above, can now be used in children aged 6 to under 12 for seasonal allergic rhinitis in the US. Approval is backed by a Phase 3 study of 446 children showing improved nasal symptoms over 14 days. RYALTRIS is now sold in 56 countries. Glenmark took over direct US commercialization of RYALTRIS from April 2026.

Likely market impact

Broadens the addressable US patient base for RYALTRIS and supports Glenmark's direct US respiratory push. Positive for revenue growth.